PTGX
Protagonist Therapeutics Inc

3,370
Mkt Cap
$5.55B
Volume
390,105.00
52W High
$96.54
52W Low
$33.70
PE Ratio
140.26
PTGX Fundamentals
Price
$88.88
Prev Close
$88.73
Open
$88.53
50D MA
$83.76
Beta
0.48
Avg. Volume
907,574.47
EPS (Annual)
$4.23
P/B
8.60
Rev/Employee
$3.45M
Loading...
Loading...
News
all
press releases
Exchange Traded Concepts LLC Sells 13,839 Shares of Protagonist Therapeutics, Inc. $PTGX
Exchange Traded Concepts LLC reduced its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 29.2% during the 3rd quarter, according to the company in its most recent...
MarketBeat·16h ago
News Placeholder
More News
News Placeholder
Protagonist Therapeutics, Inc. $PTGX Shares Purchased by Voya Investment Management LLC
Voya Investment Management LLC raised its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 8.9% during the third quarter, according to its most recent disclosure with the SEC...
MarketBeat·5d ago
News Placeholder
Assenagon Asset Management S.A. Decreases Stock Holdings in Protagonist Therapeutics, Inc. $PTGX
Assenagon Asset Management S.A. lowered its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 28.4% in the third quarter, according to the company in its most recent...
MarketBeat·5d ago
News Placeholder
Protagonist Therapeutics (NASDAQ:PTGX) Hits New 1-Year High - What's Next?
Protagonist Therapeutics (NASDAQ:PTGX) Reaches New 1-Year High - Time to Buy...
MarketBeat·13d ago
News Placeholder
Protagonist Therapeutics, Inc. $PTGX Shares Purchased by BVF Inc. IL
BVF Inc. IL increased its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 24.7% during the second quarter, according to the company in its most recent disclosure with...
MarketBeat·14d ago
News Placeholder
683 Capital Management LLC Reduces Stake in Protagonist Therapeutics, Inc. $PTGX
683 Capital Management LLC lowered its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 11.0% in the second quarter, according to its most recent disclosure with the...
MarketBeat·14d ago
News Placeholder
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $803,000 Position in Protagonist Therapeutics, Inc. $PTGX
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 56.4% in the 2nd quarter, according to its...
MarketBeat·15d ago
News Placeholder
Natixis Purchases Shares of 42,040 Protagonist Therapeutics, Inc. $PTGX
Natixis purchased a new position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The...
MarketBeat·15d ago
News Placeholder
HighVista Strategies LLC Lowers Holdings in Protagonist Therapeutics, Inc. $PTGX
HighVista Strategies LLC trimmed its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 26.3% during the 2nd quarter, according to the company in its most recent 13F...
MarketBeat·16d ago
News Placeholder
Stempoint Capital LP Trims Position in Protagonist Therapeutics, Inc. $PTGX
Stempoint Capital LP lowered its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 65.9% during the second quarter, according to the company in its most recent Form...
MarketBeat·17d ago
<
1
2
...
>

Latest PTGX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.